tbuckley/cabot-search huggingface dataset:
Appropriate Perspective and Context for Newly Approved Medications, Including Flibanserin
Authors: Irwin Goldstein, James A. Simon, Sharon J. Parish
Journal: JAMA Internal Medicine (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
First-line erlotinib in advanced non-small cell lung cancer (NSCLC) carrying an activating EGFR mutation: A multicenter academic phase II study in Caucasian patients (pts) (NCT00339586)—FIELT study group.
Authors: J. De Greve, J. P. Van Meerbeeck, J. F. Vansteenkiste, E. Teugels, C. Geers, A. Meert, P. Vuylsteke, C. N. J. Focan, J. Canon, Y. Humblet, G. J. Berchem, B. Colinet, D. Galdermans, L. Bosquée, C. A. Dooms, L. Decoster, J. Vermeij, A. Dewaele, D. C. C. Schallier
Journal: Journal of Clinical Oncology (2011)

7597 Background: Compared to chemotherapy, 1st line treatment with EGFR-TK inhibitors results in superior progression-free survival (PFS) in Asian patients with advanced NSCLC with activating EGFR TK domain mutations. We conducted a prospective study with 1st line erlotinib in Caucasian pts with EGFR TK domain mutations. Methods: Multicentre phase II study. EGFR mutation status was determined in a central lab on macro-dissected biopsies obtained from pts with advanced adenocarcinoma with a non- or past smoking history. Pts were given erlotinib, 150 mg daily till disease progression or prohibitive toxicity. The primary end point of the study was a 70% PFS at 3 months. Results: An EGFR mutation was found in 64 (28%) of 247 pts screened. Eighteen pts did not enter the study because of deterioration, withholding of consent after mutation analysis, or failing other clinical selection criteria. Forty six pts (8 male, 38 female) with median age of 72 years (35-83), median performance status of 1 (1-3) stage distribution Ib (1), IIIb (4) and IV (41) patients were included. EGFR mutations found: exon 18 (1), exon 19 (27), exon 20 (3) and exon 21 (15). Smoking history: 38 never smokers, 7 past smokers, 1 smoker. Median follow-up is 83 weeks. PFS was 83 % at 3 months and 74% at 6 months. Best response was: PR 26; SD 10, PD 10. The median time to progression and overall survival are not reached: 44+ and 56+ weeks respectively. One patient ended treatment prematurely because of skin toxicity while in PR for 83+ wks. Conclusions: In this the first formal prospective phase II genotype based study with erlotinib in first-line treatment of Caucasian pts with EGFR mutant advanced NSCLC, efficacy appears similar to the results obtained with gefitinib and erlotinib in randomized studies involving Asian patients and other first-line data with erlotinib. The study achieved its primary end point (PFS ≥ 70% at 3 months). A randomized study comparing first-line erlotinib versus chemotherapy is ongoing in Europe.
Mapping Disparities in Access to Safe, Timely, and Essential Surgical Care in Zambia
Authors: Micaela M. Esquivel, Tarsicio Uribe-Leitz, Emmanuel Makasa, Kennedy Lishimpi, Peter Mwaba, Kendra Bowman, Thomas G. Weiser
Journal: JAMA Surgery (2016)

Surgical care is widely unavailable in developing countries; advocates recommend that countries evaluate and report on access to surgical care to improve availability and aid health planners in decision making.To analyze the infrastructure, capacity, and availability of surgical care in Zambia to inform health policy priorities.In this observational study, all hospitals providing surgical care were identified in cooperation with the Zambian Ministry of Health. On-site data collection was conducted from February 1 through August 30, 2011, with an adapted World Health Organization Global Initiative for Emergency and Essential Surgical Care survey. Data collection at each facility included interviews with hospital personnel and assessment of material resources. Data were geocoded and analyzed in a data visualization platform from March 1 to December 1, 2015. We analyzed time and distance to surgical services, as well as the proportion of the population living within 2 hours from a facility providing surgical care.Surgical capacity, supplies, human resources, and infrastructure at each surgical facility, as well as the population living within 2 hours from a hospital providing surgical care.Data were collected from all 103 surgical facilities identified as providing surgical care. When including all surgical facilities (regardless of human resources and supplies), 14.9% of the population (2 166 460 of 14 500 000 people) lived more than 2 hours from surgical care. However, only 17 hospitals (16.5%) met the World Health Organization minimum standards of surgical safety; when limiting the analysis to these hospitals, 65.9% of the population (9 552 780 people) lived in an area that was more than 2 hours from a surgical facility. Geographic analysis of emergency and essential surgical care, defined as access to trauma care, obstetric care, and care of common abdominal emergencies, found that 80.7% of the population (11 704 700 people) lived in an area that was more than 2 hours from these surgical facilities.A large proportion of the population in Zambia does not have access to safe and timely surgical care; this percentage would change substantially if all surgical hospitals were adequately resourced. Geospatial visualization tools assist in the evaluation of surgical infrastructure in Zambia and can identify key areas for improvement.
Takotsubo Stress Cardiomyopathy
Authors: Ezequiel Munoz, Gloria Iliescu, Pimprapa Vejpongsa, Konstantinos Charitakis, Kaveh Karimzad, Juan Lopez-Mattei, Syed Wamique Yusuf, Konstantinos Marmagkiolis, Cezar Iliescu
Journal: Journal of the American College of Cardiology (2016)
Consensus-based recommendations for the management of juvenile dermatomyositis
Authors: Felicitas Bellutti Enders, Brigitte Bader-Meunier, Eileen Baildam, Tamas Constantin, Pavla Dolezalova, Brian M Feldman, Pekka Lahdenne, Bo Magnusson, Kiran Nistala, Seza Ozen, Clarissa Pilkington, Angelo Ravelli, Ricardo Russo, Yosef Uziel, Marco van Brussel, Janjaap van der Net, Sebastiaan Vastert, Lucy R Wedderburn, Nicolaas Wulffraat, Liza J McCann, Annet van Royen-Kerkhof
Journal: Annals of the Rheumatic Diseases (2016)

Background In 2012, a European initiative called S ingle H ub and A ccess point for pediatric R heumatology in E urope (SHARE) was launched to optimise and disseminate diagnostic and management regimens in Europe for children and young adults with rheumatic diseases. Juvenile dermatomyositis (JDM) is a rare disease within the group of paediatric rheumatic diseases (PRDs) and can lead to significant morbidity. Evidence-based guidelines are sparse and management is mostly based on physicians' experience. Consequently, treatment regimens differ throughout Europe. Objectives To provide recommendations for diagnosis and treatment of JDM. Methods Recommendations were developed by an evidence-informed consensus process using the European League Against Rheumatism standard operating procedures. A committee was constituted, consisting of 19 experienced paediatric rheumatologists and 2 experts in paediatric exercise physiology and physical therapy, mainly from Europe. Recommendations derived from a validated systematic literature review were evaluated by an online survey and subsequently discussed at two consensus meetings using nominal group technique. Recommendations were accepted if &gt;80% agreement was reached. Results In total, 7 overarching principles, 33 recommendations on diagnosis and 19 recommendations on therapy were accepted with &gt;80% agreement among experts. Topics covered include assessment of skin, muscle and major organ involvement and suggested treatment pathways. Conclusions The SHARE initiative aims to identify best practices for treatment of patients suffering from PRD. Within this remit, recommendations for the diagnosis and treatment of JDM have been formulated by an evidence-informed consensus process to produce a standard of care for patients with JDM throughout Europe.
La légionellose associée aux voyages en Europe en 1999
Authors: C Joseph
Journal: Eurosurveillance (2001)

Le plus grand nombre de cas de legionellose chez des personnes de retour de voyage a ete declare en 1999 au Reseau de surveillance europeen de la maladie des legionnaires associee aux voyages depuis le debut de ce programme en 1987. Ceci resulte de l’accr
High-Dose Intravenous Pulse Methotrexate in Patients With Eosinophilic Fasciitis
Authors: Jorre S. Mertens, Manon C. Zweers, Wietske Kievit, Hanneke K. A. Knaapen, Martijn Gerritsen, Timothy R. D. J. Radstake, Frank H. J. van den Hoogen, Marjonne C. W. Creemers, Elke M. G. J. de Jong
Journal: JAMA Dermatology (2016)

Eosinophilic fasciitis (EF) is a connective tissue disorder in which conventional treatment leads to disappointing results in a proportion of patients. Therefore, we investigated high-dose intravenous (IV) pulse methotrexate (MTX) as a treatment for EF.To examine safety and effects of monthly high-dose IV pulse MTX in EF.For this prospective single-arm study, we recruited 12 patients diagnosed with biopsy specimen-proven EF between 2006 and 2009 from the Department of Dermatology and Rheumatology at the Radboud University Medical Centre.Intravenous MTX (4 mg/kg) monthly for 5 months with folinic acid rescue 24 hours after MTX administration.The primary outcome was improvement of the modified skin score at month 5 vs baseline. Secondary outcomes were durometry, range of motion, visual analog scale scores for disease activity, and 36-Item Short Form Survey health questionnaires.Overall, 12 patients (11 women between 37-69 years old) received a median (range) monthly dose of 288 (230-336) mg MTX. Median (range) modified skin score improved from 17.5 (8.0-24.0) at baseline to 8.5 (1.0-20.0) at month 5 (P = .001). Secondary outcome measures improved significantly, except for durometer scores and range of motion of the elbows. Adverse events included gastrointestinal symptoms (n = 9), mild stomatitis (n = 5), and alopecia (n = 4).High-dose IV pulse MTX is a safe and effective treatment option in EF.clinicaltrials.gov Identifier: NCT00441961.
Is optical diagnosis sufficiently established to safely discard diminutive polyps?
Authors: Athanasios Sioulas, Ioannis Papanikolaou
Journal: Endoscopy (2016)

The current standard-of-care during colonoscopy is to resect all polyps that are identified and send them for histopathological examination. This enables subsequent determination of the optimal surveillance interval for each individual; however, significant costs associated with polypectomy, specimen analysis, and additional office visits arise from the aforementioned routine.
Essential Role of DNA Methyltransferase 1–mediated Transcription of Insulin-like Growth Factor 2 in Resistance to Histone Deacetylase Inhibitors
Authors: Hye-Young Min, Su-Chan Lee, Jong Kyu Woo, Hyun Jin Jung, Kwan Hee Park, Hae Min Jeong, Seung Yeob Hyun, Jaebeom Cho, Wooin Lee, Ji Eun Park, So Jung Kwon, Hyo-Jong Lee, Xiao Ni, Young Kee Shin, Faye M. Johnson, Madeleine Duvic, Ho-Young Lee
Journal: Clinical Cancer Research (2016)

Purpose: Histone deacetylase inhibitors (HDI) are promising anticancer therapies; however, drug resistance limits their efficacy. Here, we investigated the molecular mechanisms underlying HDI resistance, focusing on the mechanism of HDI-mediated induction of insulin-like growth factor 2 (IGF2) based on our previous study.Experimental Design: The methylation status of CCCTC-binding factor (CTCF)-binding sites in the IGF2/H19 imprinting control region (ICR) were determined by methylation-specific PCR and bisulfite sequencing. The effectiveness of single or combinatorial blockade of DNA methyltransferase 1 (DNMT1) and histone deacetylase (HDAC) was evaluated using cell viability assay and patient-derived tumor xenograft (PDX) model.Results: HDAC inhibition by vorinostat increased acetylated STAT3 (K685), resulting in transcriptional upregulation of DNMT1 DNMT1-mediated hypermethylation of CTCF-binding sites in the IGF2/H19 ICR decreased CTCF insulator activity, leading to a transcriptional upregulation of IGF2 and activation of the insulin-like growth factor 1 receptor (IGF-1R) pathway in cells with acquired or de novo vorinostat resistance. Strategies targeting DNMT1 diminished the IGF2 expression and potentiated vorinostat sensitivity in preclinical models of lung cancer with hypermethylation in the H19/IGF2 ICR. The degree of ICR hypermethylation correlated with vorinostat resistance in patient-derived lung tumors and in patients with hematologic malignancies.Conclusions: DNMT1-mediated transcriptional upregulation of IGF2 is a novel mechanism of resistance to HDIs, highlighting the role of epigenetic deregulation of IGF2 in HDI resistance and the potential value of the H19/IGF2 ICR hypermethylation and DNMT1 expression as predictive biomarkers in HDI-based anticancer therapies. Clin Cancer Res; 23(5); 1299-311. ©2016 AACR.
Pokémon Go: mobile app user guides
Authors: Nash Anderson, James Steele, Lise-Ann O'Neill, Lesley A Harden
Journal: British Journal of Sports Medicine (2016)

Pokemon Go.

Entertainment.

Requires iOS 6.0 or later or Android 4.4 and later.

Free with additional purchasing options.

Pokemon Go is a smart phone game created by Niantic featuring the original creatures from Nintendo/GAMEFREAK/Creatures. The goal is to catch and level up Pocket monsters or Pokemon and your avatar through various tasks and by visiting various physical locations (figure 1).



Figure 1 
Screenshot—Pokemon Go (screenshot from Pokemon Go. Android V.0.29.0. July 2016 Niantic 2016 Pokemon. 1985–2016 Nintendo, Creatures, GAMEFREAK). Attempting to catch a Pokemon of breed ‘Spearow’. The augmented reality transposes catchable Pokemon onto real-life locations such as this treatment couch.



It is an example of exergaming, ‘technology-driven physical activities, such as video game play, that requires participants to be physically active or exercise in order to play the …
Combination capecitabine/temozolomide (CAPTEM) in patients with neuroendocrine tumors (NETs): A single institution review.
Authors: Robert A. Ramirez, J Philip Boudreaux, Yi-Zarn Wang, David T Beyer, Eugene Woltering
Journal: Journal of Clinical Oncology (2015)

e15184 Background: Neuroendocrine tumors (NETs) are commonly treated with multimodality therapy including surgery, somatostatin analogs, targeted agents, chemotherapy and others. The combination of capecitabine and temozolomide (CAPTEM) has been suggested as a treatment option for metastatic disease, however, prospective data is accruing. We sought to review our patient population to determine efficacy and safety of CAPTEM. Methods: This retrospective review included patients with NETs who had been seen at the Louisiana State University/Ochsner NET clinic. Appropriate institutional review board approval was obtained. Patients were identified via an eVelos database. Only NET patients who had been placed on CAPTEM as previously described and received at least one cycle were included for review. Those with inadequate records or without documented follow up were excluded. Response rate (RR) was evaluated by RECIST 1.1. Results: Thirty patients (17 female) were included for review. The median age of CAPTEM initiation was 58.5 (27-77) years. Primary tumors included small bowel, 9 (30%); pancreas, 15 (50%); lung, 4 (13%); and rectum, 2 (7%). There were zero complete responses. Overall partial response (PR) occurred in 10 (33%) patients. Stable disease (SD) occurred in 12 (40%) patients. RRs by Ki-67 and sites are shown in the table. The median duration of response was 330 days. Adverse reactions included fatigue (50%), nausea (40%), cytopenias (25%) and hand foot syndrome (35%) resulting in dose reductions in 23% of patients. Conclusions: CAPTEM provided NET patients another option for treatment that generally produced a long duration of response. CAPTEM seemed to provide clinical benefit in the majority of patients regardless of primary site or Ki-67. While side effects were frequent, most patients were able to tolerate this regimen. CAPTEM may be a consideration in the treatment of NET patients while we await the results of prospective studies to confirm the efficacy of this drug combination. Response by Ki-67 % N PR, n(%) PR + SD, n(%) ≤2 7 2 (29) 6 (86) >2-20 18 7 (39) 13 (72) >20 4 1 (25) 2 (50) Response by site Rectum 2 0 2 (100) Pancreas 15 7 (47) 11 (74) Small Bowel 9 3 (33) 7 (77) Lung 4 0 2 (50)
6q Deletion in Waldenström Macroglobulinemia Is the Most Common Cytogenetic Abnormality and Is Associated with Aggressive Disease with a Trend towards Worse Survival.
Authors: Roelandt F.J. Schop, Enrique M. Ocio, Belen Gonzalez, Norma C. Gutierrez, Maria Jesus Moro, Carmen Aguilera, Jose Hernández, Ramon García-Sanz, Ruifang Xu, Jesus M. Hernandez-Rivas, Philip R. Greipp, Angela Dispenzieri, Syed M. Jalal, Martha Q. Lacy, Natalia Gonzalez-Paz, Morie A. Gertz, Jesús F. San Miguel, Rafael Fonseca
Journal: Blood (2005)
Dynamic O-(2-[18F]fluoroethyl)-L-tyrosine PET imaging for the detection of checkpoint inhibitor-related pseudoprogression in melanoma brain metastases
Authors: Sied Kebir, Laurèl Rauschenbach, Norbert Galldiks, Max Schlaak, Elke Hattingen, Jennifer Landsberg, Ralph A Bundschuh, Karl-Josef Langen, Björn Scheffler, Ulrich Herrlinger, Martin Glas
Journal: Neuro-Oncology (2016)
Evidence That GPI-AP-Specific CTLs Are Not Involved In The “escape” Of Piga mutant Hematopoietic Stem Cells In Aplastic Anemia
Authors: Takamasa Katagiri, Hiroyuki Maruyama, Shigeki Ohtake, Chizuru Saito, Kohei Hosokawa, Seishi Ogawa, Shinji Nakao
Journal: Blood (2013)
Phase I/II trial on intraoperative radiotherapy (IORT) in glioblastoma multiforme (INTRAGO).
Authors: Frank Anton Giordano, Stefanie Brehmer, Bettina Muerle, Grit Welzel, Elena Sperk, Frank Schneider, Sven Clausen, Peter Schmiedek, Christoph Groden, Daniel Hänggi, Yasser Abo-Madyan, Frederik K. Wenz
Journal: Journal of Clinical Oncology (2016)

e13503 Background: Glioblastoma recurs locally shortly after primary therapy. Intraoperative radiotherapy (IORT) may deplete remaining tumor cells and delay tumor regrowth. We conducted a dose-escalation trial using IORT with low-energy photons (Intrabeam-System). Clinicaltrials.gov ID NCT02104882. Methods: We treated 14 patients (n = 11 on trial and n = 3 enrolled in a compassionate use program) with IORT added to standard-of-care (surgery, radiochemotherapy [RCT], chemotherapy [CT]). The dose levels were 20 (level I), 30 (II) and 40 Gy (III) prescribed to the applicator surface. The primary endpoint was safety, whereas monitoring of dose-limiting toxicities (DLTs) was confined to the first 3 months after IORT. DLTs included wound healing deficits requiring surgery, cerebral bleeding/ischemia, symptomatic brain necrosis requiring surgery and early termination of RCT due to radiotoxicity. Secondary end points were progression-free (PFS) and overall survival (OS). PFS was divided into distant (D-PFS; > 1 cm to the cavity) and local PFS (L-PFS). Results: The median follow up was 11.4 months (4.5-28.2 mo). The majority of patients (12/86%) were incompletely resected and 6 patients (43%) had unresectable satellites. Eight (57%) patients had an unmethylated MGMT promoter. Of the 14 patients that received IORT, n = 7 were treated in level I, n = 3 in level II and n = 4 in level III. Twelve received adjuvant RCT, one patient declined all adjuvant therapies and one patient did not receive first-line RCT. No DLTs were observed in any level. The majority of grade III adverse events (21 of 25) were attributed to either CT or tumor progression. Radionecrosis was diagnosed in 2 patients (1 x by PET, 1 x by surgery due to suspected PD). The 6-, 12- and 18-month D-PFS / L-PFS were 92% / 100%, 76% / 80% and 38% / 53%, resepectively. The 1-year OS was 75% (median not reached). The longest survival (28.2 mo) was seen in a patient with an unmethylated MGMT promoter. Conclusions: INTRAGO enrolled a collective with predominantly unfavorable prognosis (high rate of incomplete resections and satellite lesions). The trial has not established a MTD for IORT with low-energy photons. L-PFS is seen to be consistently higher than D-PFS, suggesting efficiency of IORT. Clinical trial information: NCT02104882.